A potentially serious adverse effect of GLP-1 receptor agonists  

作　　者：Jinmiao Lu Hao Liu Qingtong Zhou Ming-Wei Wang Zhiping Li 

机构地区：[1]Department of Pharmacy,Children's Hospital of Fudan University,National Children's Medical Center,Shanghai 201102,China [2]School of Medicine,Ningbo University,Ningbo 31521l,China [3]Research Center for Deepsea Bioresources,Sanya 572025,China [4]Department of Pharmacology,School of Basic Medical Sciences,Fudan University,Shanghai 200032,China

出　　处：《Acta Pharmaceutica Sinica B》2023年第5期2291-2293,共3页药学学报（英文版）

基　　金：partially National Natural Science Foundation of China 81874325(Zhiping Li),81872915(Ming-Wei Wang)and 82073904(Ming-Wei Wang);The Science and Technology Commission of Shanghai Municipality 18DZ1910604(Zhiping Li),19XD1400900(Zhiping Li)and 19DZ1910604(Zhiping Li);National Science and Technology Major Project of China—Key New Drug Creation and Manufacturing Program 2018ZX09735—001(Ming-Wei Wang);the National Key Basic Research Program of China 2018YFA0507000(Ming-Wei Wang)。

摘　　要：To the Editor:Glucagon-like peptide-1(GLP-1)is a small intestine-derived hormone^(1,2).Its peptidic analogs include exenatide,lixisenatide,dulaglutide,liraglutide,albiglutide,semaglutide,etc.They work as GLP-1 receptor agonists(GLP-1RAs)to treat type 2 diabetes,obesity,hypertension and dyslipidemia.Among them。

关 键 词：Glucagon-like peptide-1 receptor AGONIST Clinical trial Adverse effect CONSTIPATION 

分 类 号：R969[医药卫生—药理学]